Hydrocortisone Succinat Sodic Eipico

Hydrocortisone Succinat Sodic Eipico is a sterile injectable medication containing hydrocortisone sodium succinate, a glucocorticoid used in the European market. It is supplied as a solution for intramuscular or intravenous administration. The product provides rapid systemic glucocorticoid activity for emergency management of adrenal insufficiency, severe inflammation, or allergic reactions. It requires a prescription and is not available over the counter in clinical practice by healthcare professionals.

Hydrocortisone sodium succinate is indicated for several acute medical conditions that require rapid glucocorticoid replacement or anti‑inflammatory action.

- Treatment of adrenal insufficiency, including Addison’s disease and adrenal crisis. - Management of septic shock or anaphylactic shock when immediate cortisol effect is needed. - Control of severe inflammatory or allergic reactions such as asthma exacerbations or skin eruptions. - Peri‑operative stress dosing in patients with known cortisol deficiency. - Adjunct therapy for certain autoimmune disorders under specialist supervision.

Like other systemic glucocorticoids, hydrocortisone sodium succinate can cause a range of adverse reactions, most of which are dose‑ and duration‑dependent.

Common: - Transient hyperglycemia or elevated blood glucose. - Sodium and water retention leading to mild edema. - Mood changes such as anxiety or insomnia. - Gastro‑intestinal discomfort, nausea, or dyspepsia. - Facial flushing or skin pallor. - Headache or dizziness.

Serious: - Severe hypersensitivity reactions, including anaphylaxis. - Acute adrenal suppression after abrupt discontinuation. - Infections or worsening of existing infections due to immunosuppression.

When prescribing hydrocortisone sodium succinate, clinicians should evaluate patient history and monitor for conditions that may be aggravated by glucocorticoid therapy.

- Known hypersensitivity to hydrocortisone or any formulation component. - Uncontrolled diabetes mellitus or severe hyperglycemia. - Active or latent infections, especially tuberculosis or fungal infections. - Osteoporosis, peptic ulcer disease, or recent gastrointestinal bleeding. - Psychiatric disorders, including depression or psychosis. - Pregnancy and lactation status should be assessed; use only if benefits outweigh risks. - Elderly patients may require dose adjustment due to altered metabolism.

Hydrocortisone sodium succinate can alter the pharmacokinetics or pharmacodynamics of several medicines; awareness of key interactions helps prevent adverse outcomes.

Avoid: - Concurrent use of strong CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce glucocorticoid efficacy. - Combined therapy with other systemic glucocorticoids, increasing risk of systemic toxicity.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) which may raise the risk of gastrointestinal ulceration. - Anticoagulants such as warfarin, as glucocorticoids can affect coagulation parameters. - Vaccines, particularly live attenuated vaccines, due to possible reduced immune response. - Diuretics, especially thiazides, which may exacerbate electrolyte imbalances.